Gene · 3908
LAMA2: laminin subunit alpha 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. LAMA2: laminin subunit alpha 2. Genes, record 3908. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3908
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P24043 | Laminin subunit alpha-2 | 3,122 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents47
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 51084 | P24043 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 13034 | P24043 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 14659 | P24043 | Espacenet |
| EP 4641203 A2 | 2025-10-29 | 450 | P24043 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 7643 | P24043 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 6850 | P24043 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 6850 | P24043 | Espacenet |
| JP 2025517967 A | 2025-06-12 | 450 | P24043 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 14659 | P24043 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 13034 | P24043 | Espacenet |
1 to 10 of 47
See all 47 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| OCRIPLASMIN | CHEMBL2095222 | Laminin hydrolytic enzyme | HYDROLYTIC ENZYME |
Source ChEMBL
Trials10
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT02747030 | OCRIPLASMIN | PHASE1 | ClinicalTrials.gov | |
| NCT02681809 | OCRIPLASMIN | PHASE2 | 2020-12-16 | ClinicalTrials.gov |
| NCT01429441 | OCRIPLASMIN | PHASE3 | 2016-01-11 | ClinicalTrials.gov |
| NCT00996684 | OCRIPLASMIN | PHASE2 | ClinicalTrials.gov | |
| NCT00798317 | OCRIPLASMIN | PHASE3 | 2013-01-30 | ClinicalTrials.gov |
| NCT00781859 | OCRIPLASMIN | PHASE3 | 2013-01-28 | ClinicalTrials.gov |
| NCT00428129 | OCRIPLASMIN | PHASE2 | ClinicalTrials.gov | |
| NCT00412451 | OCRIPLASMIN | PHASE2 | 2013-09-13 | ClinicalTrials.gov |
| NCT00123305 | OCRIPLASMIN | PHASE2 | ClinicalTrials.gov | |
| NCT00123266 | OCRIPLASMIN | PHASE2 | ClinicalTrials.gov |
NIH grants1,398
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | LAMA2 papers | Newest fiscal year |
|---|---|---|---|
| ZIANS003129 | Molecular and Clinical Manifestations of Matrix and Aggregate Myopathies | 25 | 2025 |
| P50NS053672 | Muscular Dystrophy Specialized Research Center | 4 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 4 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| I01BX003824 | Advanced conformational changes in NOTCH3 and cerebrovascular disease severity | 2 | 2025 |
| K12CA090628 | Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic | 2 | 2025 |
| P01HL141084 | Multiscale Systems to Elucidate Susceptibility and Cardioprotective Mechanisms in Cardio-oncology | 2 | 2025 |
| P20GM103418 | Kansas IDeA Network of Biomedical Research Excellence 5 | 2 | 2025 |
1 to 10 of 1,398Source NIH's project files
See all 1,398 nih grantsPapers2,255
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Conserved neuronal-like and secretory programs define the spatial architecture of gastroenteropancreatic neuroendocrine tumors. | J Clin Invest | 2026 | 42678737 | PubTator, text mining | PubMed |
| Nanofibrous Matrices Modulating Glioma Cell Migration and Proliferation and the Exploration of Their Molecular Mechanism. | ACS Appl Bio Mater | 2026 | 42606053 | PubTator, text mining | PubMed |
| Triple-AAV intein-mediated gene therapy ameliorates dystrophic phenotype in MDC1A mice. | Mol Ther | 2026 | 42528140 | PubTator, text mining | PubMed |
| Integrative multi-omics analysis identifies stellate cell-derived complement component 7 as a predictor of fibrosis and liver-related events in MASLD. | JHEP Rep | 2026 | 42486350 | PubTator, text mining | PubMed |
| Cause of a fatal multi-organ fat embolism syndrome in a patient with LAMA2-associated congenital muscular dystrophy. | Forensic Sci Med Pathol | 2026 | 42390674 | PubTator, text mining | PubMed |
| Polymerizing laminins: Assembly, functions and disorders. | Matrix Biol | 2026 | 42349693 | PubTator, text mining | PubMed |
| Comments on the "Unexplained multiorgan fat embolism syndrome in a 10-year-old child with LAMA2-related congenital muscular dystrophy", and on the subsequent correspondence. | Forensic Sci Med Pathol | 2026 | 42319696 | PubTator, text mining | PubMed |
| Gene-Environment Interaction Loci Associated with Refractive Error: SCAMPI Analysis. | Ophthalmol Sci | 2026 | 42293346 | PubTator, text mining | PubMed |
| The Effect of Trunk Brace Use on Motor and Pulmonary Functions in a Patient with LAMA2-Related Congenital Muscular Dystrophy: A Case Report. | Stud Health Technol Inform | 2026 | 42290440 | PubTator, text mining | PubMed |
| The Proliferation and Adipogenic/Fibrogenic Fate Commitment of FAPs via an Autocrine LAMA2/ITGβ1-FAK Pathway. | J Agric Food Chem | 2026 | 42267524 | PubTator, text mining | PubMed |
1 to 10 of 2,255
See all 2,255 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3908
GET https://conductscience.org/api/genes/v1/3908/patents?page=2